
|Videos|October 18, 2016
How Myriad's myPlan Addresses the Risk of Recurrence in Lung Cancer
Author(s)Benjamin P. Levy, MD
Benjamin P. Levy, MD, discusses how Myriad's myPlan addresses the risk of recurrence in lung cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Switching From Chemoimmunotherapy When a ROS1 Result Returns
2
Building an Adequate ROS1 Workup With RNA-Based Sequencing
3
Etentamig Improves Response, Survival in Phase 3 Trial for Relapsed/Refractory Myeloma
4
Ivonescimab Bests Pembrolizumab on Overall Survival in PD-L1+ NSCLC
5
































